parkinson
diseas
second
common
neurodegen
diseas
world
report
import
protein
involv
dopamin
receptor
desensit
essenti
parkinson
diseas
moreov
potenti
valu
pharmacolog
inactiv
g
proteincoupl
receptor
kinas
arrestin
treatment
patient
parkinson
diseas
recent
shown
studi
interact
dopamin
receptor
pharmacolog
regul
chemic
compound
interact
use
capillari
zone
electrophoresi
result
screen
compound
reveal
three
compound
remark
inhibit
dopamin
receptor
interact
among
compound
promis
therapi
parkinson
diseas
method
use
studi
great
potenti
applic
largescal
drug
screen
evalu
keyword
drug
screen
dopamin
receptor
capillari
zone
electrophoresi
proteinprotein
interact
parkinson
diseas
g
proteincoupl
receptor
gpcr
form
superfamili
heptahel
protein
mediat
variou
biolog
process
rang
neurotransmiss
hormon
control
virtual
physiolog
respons
percept
tast
smell
light
pain
kobilka
deupi
rosenbaum
et
al
upon
stimul
heptahel
receptor
undergo
conform
chang
allow
bind
heterotrimer
g
protein
lead
activ
differ
effector
signal
pathway
kobilka
deupi
gpcr
also
control
respons
activ
mechan
result
desensit
gainetdinov
et
al
whalen
et
al
one
first
step
process
involv
function
uncoupl
g
protein
receptor
process
fairli
rapid
second
minut
depend
receptor
phosphoryl
intracellular
secondmessengerregul
kinas
gpcr
kinas
grk
premont
et
al
premont
gainetdinov
secondmessengerregul
kinas
phosphoryl
activ
inact
receptor
yield
heterolog
desensit
latter
case
receptor
activ
may
becom
desensit
activ
distinct
receptor
howev
grk
specif
phosphoryl
agonistoccupi
receptor
result
homolog
desensit
reiter
lefkowitz
kelli
et
al
grk
phosphoryl
receptor
suffici
desensit
instead
serv
creat
highaffin
site
promot
bind
arrestin
protein
turn
guarante
desensit
prevent
coupl
g
protein
reiter
lefkowitz
four
distinct
mammalian
arrestin
protein
known
two
visual
cone
arrestin
restrict
phototransduct
pathway
lefkowitz
shenoy
somat
isoform
ubiquit
express
assum
regul
signal
well
intern
mani
heptahel
receptor
reiter
lefkowitz
dewir
et
al
pei
whalen
et
al
dopamin
receptor
dr
classifi
subtyp
base
pharmacolog
biochem
characterist
belong
gpcr
superfamili
andersen
et
al
neve
et
al
dr
implic
pathophysiolog
treatment
movement
disord
schizophrenia
drug
addict
emilien
et
al
goldmanrak
et
al
mehlerwex
et
al
parkinson
diseas
second
common
neurodegen
disord
caus
degener
dopaminerg
neuron
substantia
nigra
olanow
et
al
savitt
et
al
lack
dopamin
lead
disturb
basal
ganglia
circuitri
consequ
motor
deficit
dopamin
replac
therapi
ldopamin
precursor
dopamin
effect
way
correct
motor
abnorm
longterm
therapi
often
result
reduc
respons
drug
motor
complic
dyskinesia
fahn
et
al
dodd
et
al
desensit
dr
mediat
bind
phosphoryl
dr
termin
signal
cascad
oakley
et
al
macey
et
al
whalen
et
al
suppress
inhibit
could
becom
effect
strategi
enhanc
antinocicept
properti
analges
morphin
reduc
side
effect
contrast
inactiv
arrestin
protein
could
result
rel
amplifi
efficaci
endogen
exogen
dopamin
stimul
potenti
help
restor
movement
among
patient
parkinson
diseas
capillari
electrophoresi
ce
import
power
method
studi
proteinprotein
interact
ding
et
al
kostal
et
al
capillari
zone
electrophoresi
cze
probabl
common
mode
ce
cze
involv
electrophoret
separ
analyt
constant
temperatur
ph
condit
free
solut
within
capillari
compar
method
ce
obtain
concret
result
short
period
small
sampl
nanogram
holzgrab
et
al
kostal
et
al
one
key
element
desensit
dr
inhibit
activ
may
enhanc
signal
upstream
signal
pathway
dewir
et
al
dopamin
theori
parkinson
diseas
indic
dopamin
defici
basal
ganglia
brain
result
decreas
signal
dr
main
caus
diseas
obeso
et
al
calabresi
et
al
recent
studi
mechan
receptor
desensit
propos
use
target
drug
screen
dromey
pfleger
levoy
jocker
studi
use
cze
detect
interact
dr
largescal
drug
screen
indic
three
chemic
compound
remark
inhibit
said
interact
render
potenti
drug
treatment
parkinson
diseas
desensit
gpcr
depend
interact
macey
et
al
skinbjerg
et
al
use
target
protein
drug
screen
parkinson
diseas
ce
laserinduc
fluoresc
celif
propos
detect
monitor
proteinpeptid
proteinprotein
interact
effici
et
al
yang
et
al
studi
detect
stabl
complex
fitcarrestin
dr
use
celif
influenc
differ
drug
complex
could
verifi
potenti
drug
screen
method
could
develop
effect
simpl
instrument
largescal
drug
screen
evalu
figur
show
electropherogram
fitcarrestin
dr
complex
detect
celif
cze
analysi
singl
sampl
contain
fitclabel
show
two
peak
min
first
peak
repres
fitcarrestin
second
repres
free
fitc
fig
howev
cze
analysi
mixtur
fitclabel
dr
identifi
three
popul
migrat
min
fig
peak
min
repres
fitcarrestind
dr
complex
label
fitc
fitclabel
peak
min
free
fitc
peak
min
fitcarrestind
dr
complex
peak
min
detect
chromatogram
cze
analysi
mixtur
fitc
dr
concentr
without
incub
immedi
perform
confirm
whether
new
peak
appear
fitclabel
correspond
fitcarrestind
dr
complex
fitclabel
dr
result
show
fitc
bind
dr
short
period
futur
experi
neg
control
protein
either
mutant
mutant
dr
demonstr
specif
function
relev
complex
format
compound
includ
phytic
acid
ethylamin
ad
mixtur
test
pharmacolog
regul
drug
interact
mixtur
inject
uncoat
fuse
capillari
separ
differ
charg
size
conveni
obtain
inform
interact
electropherogram
compound
acut
effect
nativ
structur
target
protein
wherea
other
moder
regulatori
activ
interact
show
druglik
properti
physiolog
regul
usual
revers
mani
chemic
compound
ethylamin
acut
influenc
target
protein
irrevers
action
biomacromolecul
could
result
cell
damag
figur
show
electropherogram
ethylamin
ad
mixtur
fitcarrestin
dr
although
fitcarrestind
dr
complex
complet
inhibit
mobil
peak
significantli
increas
suggest
either
characterist
capillari
modifi
chemic
compound
affect
structur
target
protein
therefor
chemic
compound
influenc
fitcarrestind
dr
complex
similarli
ethylamin
less
druglik
properti
phytic
acid
myoinositol
hexaphosphor
acid
abund
plant
constitu
compris
edibl
legum
cereal
oil
seed
pollen
nut
report
bind
photoreceptor
arrestin
block
interact
rhodopsin
wilson
copeland
interact
predict
phytic
acid
could
alter
gpcr
desensit
investig
inhibitori
action
use
cze
phytic
acid
ad
mixtur
fitclabel
dr
fig
compar
data
illustr
panel
b
fig
fitcarrestind
dr
complex
remark
inhibit
phytic
acid
suggest
phytic
acid
detect
interact
therebi
block
bind
dr
phytic
acid
henc
promis
therapi
parkinson
diseas
ethylenediamin
ad
mixtur
fitclabel
dr
peak
fitcarrestind
dr
complex
electropherogram
disappear
fig
indic
ethylenediamin
strongli
inhibit
interact
therefor
chemic
compound
ethylenediamin
inhibit
interact
potenti
use
treatment
parkinson
diseas
screen
result
demonstr
inhibit
properti
similar
ethylenediamin
data
shown
ad
mixtur
fitclabel
dr
peak
fitcarrestin
dr
complex
electropherogram
remark
decreas
peak
decreas
increas
concentr
compound
fig
doserespons
analysi
claim
inhibitor
import
smallmolecul
inhibitor
studi
conduct
overal
result
indi
cate
remark
inhibit
interact
promis
drug
treatment
parkinson
diseas
studi
screen
potenti
drug
parkinson
diseas
use
cze
base
interact
valid
experi
use
tradit
bind
assay
immunoprecipit
gst
pulldown
conduct
demonstr
effect
compound
cell
data
screen
compound
cell
anim
model
level
clearli
need
parkinson
diseas
chronic
progress
neurodegen
movement
disord
jankov
typic
drug
screen
strategi
base
dopamin
theori
although
ldopaminelik
drug
improv
health
patient
parkinson
diseas
associ
mani
advers
effect
calabresi
et
al
dagher
robbin
specif
research
shown
longterm
treatment
ldopamin
may
trigger
symptom
schizophrenia
altern
pharmacolog
inactiv
grk
arrestin
could
provid
effect
approach
amplifi
efficaci
endogen
exogen
dopamin
stimul
help
restor
movement
among
patient
parkinson
diseas
drugdesign
target
drrelat
protein
arrestin
grk
remain
unexplor
thu
evalu
studi
util
cze
screen
potenti
drug
initi
found
three
valuabl
chemic
compound
signific
dosedepend
effect
interact
compound
promis
applic
treatment
parkinson
diseas
reduc
side
effect
although
compound
need
studi
cze
prove
effect
conveni
method
drug
screen
may
use
largescal
drug
screen
evalu
reagent
materi
dr
purchas
sigmaaldrich
st
loui
mo
usa
chemic
compound
ethylenediamin
plasmidencod
rat
kindli
provid
prof
xiang
zhou
colleg
chemistri
molecular
scienc
wuhan
univers
prof
robert
j
lefkowitz
depart
medicin
duke
univers
medic
center
respect
express
escherichia
coli
purifi
accord
publish
procedur
xiao
et
al
reagent
use
analyt
grade
apparatu
ce
experi
perform
beckman
pace
mdq
apparatu
beckmancoult
fullerton
ca
usa
lif
detector
excit
nm
emiss
nm
liquid
cool
system
uncoat
fuse
silica
capillari
yongnian
optic
fiber
china
measur
cm
id
distanc
detector
run
buffer
ce
experi
mmoll
nah
po
na
hpo
buffer
ph
solut
deioniz
water
filter
cellulos
acet
membran
filter
store
concentr
protein
determin
use
biorad
protein
assay
prepar
fitclabel
fitc
dissolv
deioniz
water
final
concentr
mmoll
aliquot
ml
mmoll
fitc
solut
mix
ml
mmoll
dilut
mmoll
sodium
bicarbon
buffer
ph
solut
mix
thoroughli
left
dark
overnight
dilut
desir
concentr
run
buffer
prior
ce
experi
new
capillari
flush
moll
naoh
min
deioniz
water
min
measur
capillari
flush
moll
naoh
min
deioniz
water
min
run
buffer
min
capillari
chamber
temperatur
control
liquid
cool
system
field
strength
capillari
vcm
normal
polar
mode
sampl
pressureinject
capillari
psi
